Audrey Gill
About Audrey Gill
Audrey Gill is a biostatistician currently working at Epic Sciences in San Diego, California. She holds a Master's degree in Bioinformatics from the University of Oregon and has extensive experience in research and data analysis in the field of cancer biomarkers.
Work at Epic Sciences
Audrey Gill currently serves as a Biostatistician at Epic Sciences, a role she has held since 2019. In this position, she applies her expertise in biostatistics to support the company's mission of providing clarity in cancer diagnostics. Prior to her current role, she worked as a Biomarker Data Analyst at Epic Sciences for five months in 2019. Her work involves analyzing complex data sets to identify biomarkers that can inform treatment decisions in oncology.
Education and Expertise
Audrey Gill holds a Master’s degree in Bioinformatics from the University of Oregon, where she studied the integration of biology and data science. She also earned a Master’s degree in Statistics from Texas Tech University, providing her with a strong foundation in statistical methodologies. Additionally, she completed her Bachelor of Science degree at Southern Methodist University. Her educational background equips her with the skills necessary for her work in biostatistics and cancer research.
Background
Audrey Gill has a diverse background in research and education. She began her academic journey at Southern Methodist University, where she served as a Teaching Assistant and Tutor from 2014 to 2016. She then worked at Texas Tech University as a Research Assistant and Tutor from 2016 to 2018. In 2018, she briefly held a position as a Graduate Research Assistant at the University of Oregon. This varied experience in academic settings has contributed to her expertise in biostatistics and research methodologies.
Research Contributions
Audrey Gill has participated in significant research projects focused on cancer biomarkers. She contributed to identifying a chromosomal instability biomarker linked to poor outcomes in castration-resistant prostate cancer. Additionally, she was involved in developing and validating circulating tumor cell enumeration as a prognostic biomarker in metastatic castration-resistant prostate cancer. Her work also includes research on circulating tumor cell chromosomal instability and neuroendocrine phenotype in this cancer type.